Company profile: IBA Lifesciences
1.1 - Company Overview
Company description
- Provider of life science technologies including the Strep-tag system for high-purity, high-yield recombinant protein purification and analysis; Strep-Tactin XT for strong, reversible binding to Twin-Strep-tag peptides; MagStrep Strep-Tactin XT beads and Strep-Tactin XT 4Flow resins for efficient purification; the MEXi mammalian cell production system; and StrepMAB-Immo for SPR analysis.
Products and services
- Strep-Tactin®XT 4Flow® Resins: Agarose-based resins for efficient protein purification, suitable for various protein classes and offering broad pH stability
- Strep-Tactin®XT: Engineered streptavidin for the Strep-tag® system, enabling strong, reversible binding to Twin-Strep-tag® peptides and facilitating various protein analytic applications
- Strep-tag® Technology: Affinity-based system for protein purification and analysis, enabling high-purity, high-yield purification of recombinant proteins using affinity tags
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IBA Lifesciences
InGen BioSciences
HQ: France
Website
- Description: Provider of mono and multiparametric in vitro diagnostic kits and products, focused on developing and marketing in vitro diagnostic tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InGen BioSciences company profile →
Evolutionary Genomics
HQ: United States
Website
- Description: Provider of a proprietary Adapted Traits platform for molecular evolution analysis to identify and validate genes impacting commercially valuable crop traits, including yield, pest resistance, and drought tolerance; offering R&D services and patented genes such as FusR1 for banana Panama disease resistance and EG261 for soybean cyst nematode resistance; collaborating on cassava brown streak disease resistance with the Bill and Melinda Gates Foundation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evolutionary Genomics company profile →
Prime Medicine
HQ: United States
Website
- Description: Provider of gene editing technologies and therapies utilizing Prime Editing to modify genetic sequences to treat a wide range of diseases. Offerings include Prime Editors for precise edits across tissues and cell types, Dual Flap Prime Editing for broader edits, PASSIGE for inserting large gene-sized sequences, and Prime-Edited Cell Therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prime Medicine company profile →
Bioline
HQ: United Kingdom
Website
- Description: Provider of fast, easy-to-use, guaranteed-to-work products developed by scientists to help customers focus on their scientific goals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioline company profile →
Bluebird Bio
HQ: United States
Website
- Description: Provider of gene therapies for severe genetic and rare diseases, developing gene addition treatments that modify patient cells to address underlying genetic causes using lentiviral vectors. Products include LentiGlobin for sickle cell disease, Lenti-D for cerebral adrenoleukodystrophy, and Zynteglo for beta-thalassemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluebird Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IBA Lifesciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IBA Lifesciences
2.2 - Growth funds investing in similar companies to IBA Lifesciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IBA Lifesciences
4.2 - Public trading comparable groups for IBA Lifesciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →